Board of Directors
Glauco R. Souza, Ph.D.
Glauco R. Souza, PhD, Co-Founder, Director, former President and CSO of Nano3D Biosciences, and now Director of Global Business Development and Innovation at Greiner Bio-one (GBO). The inventor or co-inventor of all eleven patents related to magnetic 3D cell culture, Glauco is a major influence in the field of 3D cell culture. After GBO IP acquisition, Dr. Souza took the position at GBO to oversee 3D cell culture operations and marketing globally. He is instrumental in any needed product and technical support to be provided by GBO.
He is was a former Adjunct Assistant Professor at University of Texas Health Science Center at Houston. His work in 3D cell culture was selected for the Short List of the 2017 Lush Prize for outstanding research producing an effective non-animal safety test Prior to co-founding Nano3D BioSciences, he was an Odyssey Scholar at The University of Texas M. D. Anderson Cancer Center. Glauco R. Souza has a B.S. in Chemistry, and M.S. and Ph.D. in Physical Chemistry from The George Washington University.
Thomas C. Killian, Ph.D.
Thomas C. Killian, Ph.D. received a BA in Physics in 1991 from Harvard University, and then attended Cambridge University on a Marshall Scholarship, where he earned an MPhil in physical chemistry in 1993. He received his PhD in atomic physics at the Massachusetts Institute of Technology in 1999, and then completed a post-doctoral fellowship at the National Institute of Standards and Technology. In 2001, Dr. Killian became an Assistant Professor of Physics and Astronomy at William Marsh Rice University where he conducts research on the properties of matter at temperatures as low as a few billionths of a degree above absolute zero.
He served as the Chair of the Department of Physics and Astronomy from 2012-2016 and is currently the Associate Dean for Strategic Planning in the Wiess School of Natural Sciences at Rice. He is also a co-founder and Director of ChemoSen3D, Inc., which is developing assays that use a patient’s own cells to identify the optimal therapeutic treatment for cancer.
Tim McGrath is a veteran of the biotech industry. As the president of Genosys Biotechnologies, revenue grew from $2M to $40M, operations were expanded to the UK, Germany and Japan, and he managed the sale of the company to Sigma-Aldrich. Additionally, Tim was the CEO of Xeotron and is a co-founder and former CEO of the Oligo Factory. During his career he has been an advisor to a number of biotech companies as a consultant and/or board member. In his 30+ years in the industry has held various positions at Millipore, Zymark, and Beckman Instruments.
Mr. McGrath holds a BS and MS degree in Zoology and Biochemistry from Texas A&M University.
Matt Lenhart has been an Energy Trader for the last two decades. He also invests in private companies. He received his BS from Louisiana State University.
3D Cell Culture • Biotechnology • Clinical Diagnostics • Nanoparticles